Integrated Financial Statements From 2010 to 2026
| INBP Stock | USD 0.38 0.01 2.70% |
Check Integrated Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Integrated Biopharma's main balance sheet or income statement drivers, such as , as well as many indicators such as . Integrated financial statements analysis is a perfect complement when working with Integrated Biopharma Valuation or Volatility modules.
Integrated |
Integrated Biopharma OTC Stock Profit Margin Analysis
Integrated Biopharma's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Integrated Biopharma Profit Margin | 0.04 % |
Most of Integrated Biopharma's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Integrated Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Integrated Biopharma has a Profit Margin of 0.0411%. This is 98.64% lower than that of the Personal Products sector and 102.54% lower than that of the Consumer Staples industry. The profit margin for all United States stocks is 103.24% lower than that of the firm.
Integrated Biopharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Integrated Biopharma's current stock value. Our valuation model uses many indicators to compare Integrated Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Integrated Biopharma competition to find correlations between indicators driving Integrated Biopharma's intrinsic value. More Info.Integrated Biopharma is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers reporting about 0.26 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Integrated Biopharma is roughly 3.77 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Integrated Biopharma's earnings, one of the primary drivers of an investment's value.About Integrated Biopharma Financial Statements
Integrated Biopharma shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Integrated Biopharma investors may analyze each financial statement separately, they are all interrelated. The changes in Integrated Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on Integrated Biopharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey. Integrated Biopharma operates under Packaged Foods classification in the United States and is traded on OTC Exchange. It employs 147 people.
Pair Trading with Integrated Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Integrated Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Integrated Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against Integrated OTC Stock
The ability to find closely correlated positions to Integrated Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Integrated Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Integrated Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Integrated Biopharma to buy it.
The correlation of Integrated Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Integrated Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Integrated Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Integrated Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Integrated OTC Stock Analysis
When running Integrated Biopharma's price analysis, check to measure Integrated Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Integrated Biopharma is operating at the current time. Most of Integrated Biopharma's value examination focuses on studying past and present price action to predict the probability of Integrated Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Integrated Biopharma's price. Additionally, you may evaluate how the addition of Integrated Biopharma to your portfolios can decrease your overall portfolio volatility.